Clinical Trial Update: A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 rollover trial evaluating lumacaftor in combination with ivacaftor in individuals 12 years and older with cystic fibrosis; the study completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation | Phase 3 | Status: COMPLETED | Results posted: 2017-05-12